-
Product Insights
Tardive Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Tardive Dyskinesia - Drugs In Development, 2023’, provides an overview of the Tardive Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tardive Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Leukodystrophies – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukodystrophies - Drugs In Development, 2023’, provides an overview of the Leukodystrophies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukodystrophies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyskinesia - Drugs In Development, 2023’, provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Contera Mgmt – Contera Park Ostrava D1 – Moravskoslezsky
Equip yourself with the essential tools needed to make informed and profitable decisions with our Contera Mgmt - Contera Park Ostrava D1 - Moravskoslezsky report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – JM-010
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry JM-010 Drug Details JM-010 (CTP-010) is under development for the treatment of levodopa-induced dyskinesia...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movements. Its symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. However, the disease can be controlled by a healthy lifestyle and medication. The Dyskinesia pipeline market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...